Merit Medical Systems announced that Sheri Lewis will join as Executive Vice President of Global Operations on 31 August 2026. Lewis brings 30 years of experience in global operations, manufacturing, and supply chain management, having previously held senior positions at SkinHealth Systems, Avantor, Medtronic, and Honeywell. Lewis will replace Neil Peterson, who is transitioning to Senior Advisor to ensure continuity until 5 March 2027. Peterson has served Merit for over 32 years, including four years as Chief Operating Officer. Merit Medical, founded in 1987, manufactures medical devices for interventional, diagnostic, and therapeutic procedures. The company employs approximately 7,500 people worldwide.

Merit Medical Systems reported Q2 2026 revenue of $418.8 million, up 9.5% year-on-year and beating analyst estimates of $405.3 million. The medical device company's non-GAAP profit of $1.19 per share exceeded consensus by 24%. The strong performance was driven by recent acquisitions, including Biolife and the C2 CryoBalloon, alongside organic growth in core platforms like Vascular Intervention and Cardiac Therapies. CEO Martha Aronson noted the company achieved its strongest quarterly organic growth in three years. Merit Medical raised its full-year revenue guidance to $1.64 billion at the midpoint, up from $1.62 billion, and lifted adjusted EPS guidance to $4.30. Operating margin expanded to 14.4% from 12.3% year-on-year.

Merit Medical Systems reported second-quarter revenue of $418.8 million, up 10% year-over-year, driven by broad-based demand across its product portfolio. Organic constant-currency growth reached 9%, the company's strongest quarterly performance in three years. Non-GAAP earnings per share increased 18%, whilst free cash flow totalled nearly $52 million. US sales rose 12% to $26.1 million, and international sales grew 5% to $7.3 million. The BioLife acquisition is expected to generate approximately $23 million in annualised revenue for 2026. View Point Medical's OneMark system launched in the US, expanding Merit's oncology market opportunity. Merit raised its 2026 outlook, now expecting 6.9%–7.6% constant-currency revenue growth and non-GAAP EPS of $4.25–$4.35.